Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Summary

This is a federal grant funding opportunity issued by the National Institutes of Health (NIH) under the Clinical and Translational Science Award (CTSA) Program. It is a limited competition opportunity using the UG3/UH3 award mechanism, which is a phased cooperative agreement designed to support collaborative and innovative acceleration of clinical and translational science. Clinical trials are optional under this announcement. The opportunity opened in December 2024 and remains open through October 2027.

Risks & flags

• Limited competition designation restricts eligible applicants, potentially favoring existing CTSA hub institutions or specific prior awardees.
• No explicit eligibility criteria or scope details provided in the synopsis, making it difficult for new entrants to assess competitiveness.
• Extremely long open window (Dec 2024 – Oct 2027) may indicate rolling or invitation-only submission cycles rather than open competition.